Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals Inc. is a global biotechnology company focused on the development and commercialization of therapies for autoimmune and inflammatory diseases. The company's flagship product, Lupkynis, is approved for the treatment of lupus nephritis, a serious complication of systemic lupus erythematosus. Aurinia specializes in innovative treatments targeting immune system pathways to address unmet medical needs.
Company News
The American College of Rheumatology has updated its guidelines for treating lupus nephritis, recommending early use of triple therapy (mycophenolate mofetil, glucocorticoids, and either Benlysta or a calcineurin inhibitor). However, current practice often delays initiating triple therapy until initial treatment failure.
Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler raised the price target for Wix.com Ltd. (NASDAQ: WIX) from $146 to $165. Piper Sandler analyst Clarke Jeffries maintained an Overweight rati...
The biotech's premium valuation doesn't seem to be sitting well with investors.
Aurinia has gone all hands on deck to provide LUPKYNIS a successful launch. See why I prefer watching this one from the sidelines.